AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 19 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Dendritic cells pulsed with melanoma antigens can stimulate specific immune responses that are associated with tumor regression, researchers in Texas have found.
J. Banchereau and colleagues at Baylor Institute for Immunology Research, Dallas, vaccinated 18 patients who had metastatic melanoma with CD34(+) progenitor-derived autologous dendritic cells (DCs), including Langerhans cells. The DCs were pulsed with peptides derived from four melanoma antigens [(MelAgs) MelanA/MART-1, tyrosinase, MAGE-3, and gp100], as well as influenza matrix peptide (Flu-MP) and keyhole limpet hemocyanin (KLH) as control antigens.
DCs induced an immune response to control antigens (KLH, Flu-MP), along with an enhanced immune response to one or more MelAgs, in 16 of 18 patients, noted Banchereau and coworkers. Ten of these responded to >2 MelAgs. The two patients who did not respond to either control or tumor antigens experienced rapid tumor progression, they added.
DC injections were well tolerated except for progressive vitiligo in two patients ("Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine," Cancer Res September 2001;61(17):6451-6458).
"Of 17 patients with evaluable disease, six of ... <=)2 MelAgs had progressive disease 10 weeks after study entry, in contrast to tumor progression in only one of 10 patients with immunity to>